JPWO2023079177A5 - - Google Patents
Info
- Publication number
- JPWO2023079177A5 JPWO2023079177A5 JP2024527216A JP2024527216A JPWO2023079177A5 JP WO2023079177 A5 JPWO2023079177 A5 JP WO2023079177A5 JP 2024527216 A JP2024527216 A JP 2024527216A JP 2024527216 A JP2024527216 A JP 2024527216A JP WO2023079177 A5 JPWO2023079177 A5 JP WO2023079177A5
- Authority
- JP
- Japan
- Prior art keywords
- lurbinectedin
- administered
- atezolizumab
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21383013 | 2021-11-08 | ||
| EP21383013.6 | 2021-11-08 | ||
| PCT/EP2022/081155 WO2023079177A1 (en) | 2021-11-08 | 2022-11-08 | Lurbinectedin and atezolizumab combinations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540417A JP2024540417A (ja) | 2024-10-31 |
| JP2024540417A5 JP2024540417A5 (https=) | 2025-11-18 |
| JPWO2023079177A5 true JPWO2023079177A5 (https=) | 2025-11-18 |
Family
ID=78820304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024527216A Pending JP2024540417A (ja) | 2021-11-08 | 2022-11-08 | ルルビネクテジン及びアテゾリズマブの組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240415834A1 (https=) |
| EP (1) | EP4430075A1 (https=) |
| JP (1) | JP2024540417A (https=) |
| KR (1) | KR20240099455A (https=) |
| AU (1) | AU2022381992A1 (https=) |
| CA (1) | CA3237009A1 (https=) |
| IL (1) | IL312263A (https=) |
| MX (1) | MX2024005589A (https=) |
| WO (1) | WO2023079177A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228595A1 (en) * | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Use of compound ia in the treatment of cancers including combination therapy with atezolizumab. |
| WO2025228594A1 (en) * | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102232L (sv) | 2001-06-25 | 2003-02-06 | Anoto Ab | Förfarande och anordning i ett digitalt kommunikationssystem |
| GB0119243D0 (en) | 2001-08-07 | 2001-10-03 | Pharma Mar Sa | Antitumoral analogs of ET-743 |
| JP2023503318A (ja) * | 2019-11-21 | 2023-01-27 | ファルマ、マール、ソシエダード、アノニマ | ルルビネクテジン製剤で小細胞肺がんを処置する方法 |
-
2022
- 2022-11-08 US US18/703,491 patent/US20240415834A1/en active Pending
- 2022-11-08 JP JP2024527216A patent/JP2024540417A/ja active Pending
- 2022-11-08 MX MX2024005589A patent/MX2024005589A/es unknown
- 2022-11-08 CA CA3237009A patent/CA3237009A1/en active Pending
- 2022-11-08 AU AU2022381992A patent/AU2022381992A1/en active Pending
- 2022-11-08 EP EP22814358.2A patent/EP4430075A1/en active Pending
- 2022-11-08 KR KR1020247019194A patent/KR20240099455A/ko active Pending
- 2022-11-08 IL IL312263A patent/IL312263A/en unknown
- 2022-11-08 WO PCT/EP2022/081155 patent/WO2023079177A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102439911B1 (ko) | 제약학적 복합제제 | |
| US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| CN113164500A (zh) | 治疗去势抵抗性和去势敏感性前列腺癌的方法 | |
| US12403154B2 (en) | Administration of sting agonist and checkpoint inhibitors | |
| WO2017004092A1 (en) | Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer | |
| US20240415834A1 (en) | Lurbinectedin and atezolizumab combinations | |
| WO2020249018A1 (zh) | 治疗驱动基因阳性肺癌的联用药物组合物 | |
| JP7352582B2 (ja) | Ｓｕｍｏ活性化酵素阻害剤及び抗ｃｄ２０抗体の投与 | |
| WO2022101255A1 (en) | Lurbinectedin and irinotecan combinations | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| US12419890B2 (en) | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors | |
| JPWO2023079177A5 (https=) | ||
| US20230218618A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd38 antibodies | |
| US20240390360A1 (en) | Therapeutic Combinations Of Orally Administered Paclitaxel, A P-gp Inhibitor, And A Checkpoint Inhibitor For The Treatment Of Solid Tumors | |
| WO2024263643A1 (en) | Compositions comprising antineoplastons and methods of treating breast cancer | |
| WO2024263801A2 (en) | Compositions comprising antineoplastons and methods of treating ovarian cancer | |
| EP4731792A2 (en) | Compositions comprising antineoplastons and methods of treating lung cancer | |
| CN116265030A (zh) | 包含酪氨酸激酶抑制剂德立替尼的药物组合 |